XENON ASSOCIE A UN ANTAGONISTE DES RECEPTEURS NMDA POUR LUTTER CONTRE UNE PROLIFERATION TUMORALE DANS LE SYSTEME NERVEUX CENTRAL

摘要

The invention relates to a drug combination including gaseous xenon and at least one NMDA receptor antagonist in liquid or solid form in order to treat or slow tumour proliferation of cells in the central nervous system in a human being, in particular astrocyte glia and/or the precursors thereof. The NMDA receptor antagonist is preferably memantine or nitromemantine. The proportion of xenon is 10 % to 80 % by volume.